<DOC>
	<DOCNO>NCT02829931</DOCNO>
	<brief_summary>The main purpose study evaluate safety tolerability nivolumab , give combination hypofractionated stereotactic re-irradiation recurrent high grade glioma .</brief_summary>
	<brief_title>Hypofractionated Stereotactic Irradiation With Nivolumab Patients With Recurrent High Grade Gliomas</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Histologically confirm diagnosis World Health Organization ( WHO ) Grade III IV malignant glioma . Documented recurrence diagnostic biopsy contrast enhance magnetic resonance imaging ( MRI ) perform within 28 day entry trial per Response Assessment NeuroOncology ( RANO ) criterion . Maximum diameter enhance tumor ( target lesion ) ≤ 4 cm . An interval least 6 month end prior radiation therapy require unless new recurrence outside previous radiotherapy treatment field . Previous first line treatment least standard dose radiotherapy ( total dose ≥ 54 Gy ) temozolomide An interval ≥ 4 week since surgical resection prior study treatment . An interval ≥ 4 week last administration investigational agent , bevacizumab , prior cytotoxic therapy . ≥18 year age day sign informed consent . Karnofsky performance status 70 high . Demonstrate adequate organ function . All screen lab perform within 14 day treatment initiation . Resting baseline O2 saturation pulse oximetry ≥ 92 % rest . Must recover toxic effect prior therapy ( ≤ Grade 1 ) . Willing able provide write informed consent trial . Life expectancy ≥ 12 week Women childbearing potential ( WOCBP ) negative urine serum pregnancy within 72 hour prior receive first dose study medication . If urine test positive confirm negative , serum pregnancy test require . WOCBP willing use 2 method birth control surgically sterile , abstain heterosexual activity course study 120 day last dose study medication . Males agree use adequate method contraception start first dose study therapy 120 day last dose study therapy . Has three recurrence high grade glioma . Previous recurrence low grade glioma consider . Has receive reradiation recurrent disease ( standard frontline adjuvant radiation therapy ) . Recurrent tumor near brainstem optic chiasm must receive prior radiation therapy . Has infratentorial , leptomeningeal evidence recurrent disease . Has recurrent persistent tumor ( enhance area ) great 4 cm maximum diameter . Has prior treatment Gliadel unless administer first line treatment least 3 month prior study treatment . Is unable ( due existent medical condition ) unwilling contrast enhance MRI brain . Is currently participate participate study investigational agent use investigational device within 4 week first dose treatment . Has diagnosis immunodeficiency receive systemic immunosuppressive therapy within 7 day prior first dose trial treatment . Physiologic dose steroid therapy ( ≤ 10 mg/day prednisone equivalent ) allow . Has prior chemotherapy , target small molecule therapy , monoclonal antibody within 4 week prior study Day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due agent administer 4 week earlier . Has know additional malignancy progress require active treatment . Exceptions include basal cell carcinoma skin , squamous cell carcinoma skin , situ cervical cancer undergone potentially curative therapy . Has active autoimmune disease require systemic treatment within past 3 month document history clinically severe autoimmune disease , syndrome require systemic steroid immunosuppressive agent . Potential participant vitiligo resolve childhood asthma/atopy would exception rule . Potential participant require intermittent use bronchodilator local steroid injection would exclude study . Potential participant hypothyroidism stable hormone replacement Sjorgen 's syndrome exclude study . Has evidence interstitial lung disease active , noninfectious pneumonitis . Has active infection require systemic therapy . Had major surgical procedure , open biopsy , significant traumatic injury within 28 day prior day 1 treatment study . Requires escalate chronic supraphysiologic dos corticosteroid ( &gt; 10 mg/day prednisone equivalent ) . Has history current evidence condition , therapy , laboratory abnormality might confound result trial , interfere participation full duration trial , best interest participant , opinion treat investigator . Has know psychiatric substance abuse disorder would interfere cooperation requirement trial . Is pregnant breastfeeding , expect conceive father child within project duration trial , start prescreening screen visit 120 day last dose trial treatment . Has receive prior therapy antiPD1 , antiPDL1 , antiPDL2 , antiCD137 , antiCytotoxic Tlymphocyteassociated antigen4 ( CTLA4 ) antibody ( include ipilimumab antibody drug specifically target Tcell costimulation checkpoint pathway ) . Has know history Human Immunodeficiency Virus ( HIV ) ( HIV 1/2 antibody ) . Has know active Hepatitis B ( e.g. , HBsAg reactive ) Hepatitis C Virus ( HCV ) ( e.g. , HCV RNA [ qualitative ] detect ) . Has receive live vaccine within 30 day prior first dose trial treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>recurrent glioma</keyword>
	<keyword>high grade glioma</keyword>
	<keyword>head neck disease</keyword>
	<keyword>grade III glioma</keyword>
	<keyword>grade IV glioma</keyword>
	<keyword>radiation therapy</keyword>
</DOC>